Can Vemurafenib Induce Vitiligo in Metastatic Melanoma Patients?
作者信息
Ruiz-Villaverde Ricardo, Sánchez-Cano Daniel
机构信息
Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Internal Medicine Unit, Santa Ana Hospital, Motril, Granada, Spain.
出版信息
Balkan Med J. 2016 Jan;33(1):115-6. doi: 10.5152/balkanmedj.2015.15157. Epub 2016 Jan 1.
Abstract
摘要
相似文献
1
Can Vemurafenib Induce Vitiligo in Metastatic Melanoma Patients?维莫非尼能否诱发转移性黑色素瘤患者出现白癜风？
Balkan Med J. 2016 Jan;33(1):115-6. doi: 10.5152/balkanmedj.2015.15157. Epub 2016 Jan 1.
2
Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.2例接受维莫非尼治疗转移性黑色素瘤的患者出现白癜风。
J Am Acad Dermatol. 2013 Jul;69(1):e28-9. doi: 10.1016/j.jaad.2013.01.012.
3
Vemurafenib: in unresectable or metastatic melanoma.威罗菲尼：适用于不可切除或转移性黑色素瘤。
BioDrugs. 2012 Oct 1;26(5):325-34. doi: 10.2165/11209860-000000000-00000.
4
Vemurafenib. Value unclear in metastatic melanoma.维莫非尼。在转移性黑色素瘤中的价值尚不明确。
Prescrire Int. 2012 Dec;21(133):288-90.
5
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.维莫非尼单剂量人体药代动力学和代谢产物研究。
Pharmacol Res Perspect. 2015 Mar;3(2):e00113. doi: 10.1002/prp2.113.
6
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.维莫非尼治疗 BRAF(V600) 突变转移性黑色素瘤患者：一项开放性、多中心、安全性研究。
Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.
7
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.黑色素瘤患者中的白癜风：正常组织抗原可成为癌症免疫治疗的靶点。
J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4.
8
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.接受脑转移BRAF-V600突变黑色素瘤治疗的患者脑脊液中维莫非尼的浓度。
Melanoma Res. 2015 Aug;25(4):302-5. doi: 10.1097/CMR.0000000000000162.
9
Drug safety evaluation of vemurafenib in the treatment of melanoma.维莫非尼治疗黑色素瘤的药物安全性评价。
Expert Opin Drug Saf. 2013 Sep;12(5):767-75. doi: 10.1517/14740338.2013.813017. Epub 2013 Jun 26.
10
Vemurafenib for the treatment of melanoma.威罗菲尼治疗黑色素瘤。
Expert Opin Pharmacother. 2012 Dec;13(17):2533-43. doi: 10.1517/14656566.2012.737780. Epub 2012 Oct 24.
引用本文的文献
1
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.在晚期黑色素瘤患者中接受 BRAF 和 MEK 抑制剂联合治疗时出现的脂膜炎和白癜风：治疗疗效的潜在预测作用。
PLoS One. 2019 Apr 2;14(4):e0214884. doi: 10.1371/journal.pone.0214884. eCollection 2019.
本文引用的文献
1
Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.2例接受维莫非尼治疗转移性黑色素瘤的患者出现白癜风。
J Am Acad Dermatol. 2013 Jul;69(1):e28-9. doi: 10.1016/j.jaad.2013.01.012.
2
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.白癜风是 III 期和 IV 期转移性黑色素瘤患者的独立有利预后因素：来自单机构基于医院的观察队列研究的结果。
Ann Oncol. 2010 Feb;21(2):409-414. doi: 10.1093/annonc/mdp325. Epub 2009 Jul 21.
3
Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features.白癜风与黑色素瘤相关色素减退（MAH）：共同特征与鉴别特征
J Dtsch Dermatol Ges. 2008 Dec;6(12):1053-9. doi: 10.1111/j.1610-0387.2008.06755.x. Epub 2008 May 7.
4
Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?利用自身免疫（白癜风）治疗黑色素瘤：神话还是现实？
Ann N Y Acad Sci. 2007 Sep;1110:410-25. doi: 10.1196/annals.1423.043.
Zotero 插件